eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
July 27, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
Colorectal Cancer Alliance Appoints Avi Benaim to Board of Directors
June 29, 2018 11:08 ET
|
Colorectal Cancer Alliance
Washington, D.C., June 29, 2018 (GLOBE NEWSWIRE) -- National non-profit the Colorectal Cancer Alliance today announced the appointment of Avi Benaim, Founder and President of A.B.E. Networks, to its...
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
June 06, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
Colorectal Cancer Alliance CEO Statement on the Proposed American Cancer Society Screening Guideline
May 30, 2018 10:12 ET
|
Colorectal Cancer Alliance
Washington, D.C., May 30, 2018 (GLOBE NEWSWIRE) -- The increasing incidence of colorectal cancer in younger adults is an epidemic within the cancer community. By 2030, 10.9 percent of all colon...
Colorectal Cancer Prevention Program Launches in Philadelphia to Significantly Increase Screening Rates, Save Lives, and End this Disease
May 15, 2018 09:08 ET
|
Colorectal Cancer Alliance
Philadelphia, PA, May 15, 2018 (GLOBE NEWSWIRE) -- March Forth, a Colorectal Cancer Alliance prevention and screening initiative, today announced the launch of its Philadelphia colorectal cancer...
Colorectal Cancer Alliance Announces Up To $775,000 In Available Research Funding
May 14, 2018 10:37 ET
|
Colorectal Cancer Alliance
Washington, D.C., May 14, 2018 (GLOBE NEWSWIRE) -- The Colorectal Cancer Alliance (the Alliance) has announced up to $775,000 in available funding for research in young-onset colorectal cancer,...
Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
May 14, 2018 08:15 ET
|
Treos Bio Corp.
SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
May 11, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
April 26, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
April 16, 2018 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...